Periodic Reporting for period 2 - Solnatide (Exploration of safety, tolerability and clinical efficacy of Solnatide IMP in patients infected with the 2019 new coronavirus)

Approx. 30% of hospitalised COVID-19 patients develop the condition Acute Respiratory Distress Syndrome (ARDS). This is a life-threatening lung dysfunction characterised by the development of a Pulmonary Permeability Oedema (PPO - liquid in the lung tissue) that prevents...